Current situation facing the needs of the scenarios from the deliverables I2.1.1 and I2.2.1

In this document we present the main issues that we have to face in order to define a Software Product Line (SPL) for Broadcasting Systems. These issues were identified through requirement analysis and refactoring of SEDUITE which are described in two internal deliverables: a) D.2.2.1: Introduces the requirements (functional and non-functional) of a Broadcasting System by using a case study based on large gatherings (e.g., concerts, competitions, parties, etc.). b) D.2.1.1: Explains the definition of SEDUITE as a SPL by identifying the different assets and products that make part of it. In particular, from each deliverable different questions were raised. We use these questions to identify the issues that we need to face and to guide the redaction of this document. We classify the questions according to three main topics: (i) user assistance (cf. Section 2), (ii) building and evolution of the SPL (cf. Section 3) and (iii) kinds of variability (cf. Section 4) The questions from the D.2.2.1 deliverable are identified with I.x and those from D.2.1.1 with Q.x. In both cases, the 'x' represents the number of the question in the deliverable. Additionally, we include the results of two questionnaires intended for consumers of information (i.e., professor and students) from broadcasting system in academic institutions

Trabectedin and its potential in the treatment of soft tissue sarcoma

Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA repair machinery. Phase I trials have established the standard regimen as 1500 μg/m2 24-hour continuous infusion repeated every 3 weeks. Several phase II trials have shown response in 5%–10% of unselected patients with soft tissue sarcoma failing prior chemotherapy and disease stabilisation in 30%–40%. Furthermore, prolonged disease control has been described in 15%–20% of patients. Toxicities are mainly haematological and hepatic with grade 3–4 neutropenia and thrombocytopenia observed in approximately 50% and 20% of patients respectively, and grade 3–4 elevation of liver enzymes observed in 35%–50% of patients treated with trabectedin. Current research focuses on the identification of predictive factors for patients with soft tissue sarcoma treated with trabectedin

SPLEMMA: A Generic Framework for Controlled-Evolution of Software Product Lines

International audienceManaging in a generic way the evolution process of feature- oriented Software Product Lines (SPLs) is complex due to the number of elements that are impacted and the heterogeneity of the SPLs regarding artifacts used to define them. Existing work presents specific approaches to manage the evolution of SPLs in terms of such artifacts, i.e., assets, feature models and relation definitions. Moreover stakeholders do not necessarily master all the knowledge of the SPL making its evolution difficult and error-prone without a proper tool support. In order to deal with these issues, we introduce SPLEmma, a generic framework that follows a Model Driven Engineering approach to capture the evolution of a SPL independently of the kind of assets, technologies or feature models used for the product derivation. Authorized changes are described by the SPL maintainer and captured in a model used to generate tools that guide the evolution process and preserve the consistency of the whole SPL. We report on the application of our approach on two SPLs: YourCast for digital signage systems, and SALOON, which enables generation of configurations for cloud providers

Current situation facing the needs of the scenarios from the deliverables I2.1.1 and I2.2.1

In this document we present the main issues that we have to face in order to define a Software Product Line (SPL) for Broadcasting Systems. These issues were identified through requirement analysis and refactoring of SEDUITE which are described in two internal deliverables: a) D.2.2.1: Introduces the requirements (functional and non-functional) of a Broadcasting System by using a case study based on large gatherings (e.g., concerts, competitions, parties, etc.). b) D.2.1.1: Explains the definition of SEDUITE as a SPL by identifying the different assets and products that make part of it. In particular, from each deliverable different questions were raised. We use these questions to identify the issues that we need to face and to guide the redaction of this document. We classify the questions according to three main topics: (i) user assistance (cf. Section 2), (ii) building and evolution of the SPL (cf. Section 3) and (iii) kinds of variability (cf. Section 4) The questions from the D.2.2.1 deliverable are identified with I.x and those from D.2.1.1 with Q.x. In both cases, the 'x' represents the number of the question in the deliverable. Additionally, we include the results of two questionnaires intended for consumers of information (i.e., professor and students) from broadcasting system in academic institutions

End-User Modelling

National audienceno abstrac

Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment

Background: The impact of compliance to clinical practice guidelines (CPG) on outcomes and/or costs of care has not been completely clarified.Objective: To estimate relationships between medical expenditures and compliance to CPG for initial sarcoma treatment.Research design: Selected cohorts of patients diagnosed with sarcoma in 2005 and 2006, and treated at the University hospital and/or the cancer centre of the Rhône-Alpes region, France (n=90). Main outcome measurements were: patient characteristics, compliance with CPG, health outcomes, and costs. Data were mainly extracted from patient records. The logarithm of treatment costs was modelled using linear and Tobit regressions.Results: Rates of compliance with CPG were 86%, 66%, 88%, 89%, and 95% for initial diagnosis, primary surgical excision, wide surgical excision, chemotherapy, and radiotherapy, respectively. Total average costs reached €24,439, with €1,784, €11,225, €10,360, and €1,016 for diagnosis, surgery (primary and wide surgical excisions), chemotherapy, and radiotherapy, respectively. Compliance of diagnosis with CPG decreased the cost of diagnosis, whereas compliance of primary surgical excision increased the cost of chemotherapy. Compliance of chemotherapy with CPG decreased the cost of radiotherapy.Conclusion: Since chemotherapy is one of the major cost drivers, these results support that compliance with guidelines increases medical care expenditures in short term.Oncology; Sarcoma; Cost; Clinical guidelines; Efficacy; Medical Practices; Government Policy; Regulation; Public Health